Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition

11 Jul 2016

Abstract excerpt

EZH2 is a component of polycomb repressive complex 2 (PRC2) and functions as an H3K27 methyltransferase. Loss-of-function mutations in EZH2 are associated with poorer outcomes in patients with myeloproliferative neoplasms (MPNs), particularly those with primary myelofibrosis (MF [PMF]). To determine how EZH2 insufficiency is involved in the pathogenesis of PMF, we generated mice compound for an Ezh2 conditional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27401345
DOI: 10.1084/jem.20151121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibitionPMID 27401345Read ↗

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasmSemantic proximity Read ↗

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent mannerSemantic proximity Read ↗

Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosisSemantic proximity Read ↗

PRC2 insufficiency causes p53-dependent dyserythropoiesis in myelodysplastic syndrome.Semantic proximity Read ↗

EZH2 in Myeloid Malignancies.Semantic proximity Read ↗

[Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].Semantic proximity Read ↗

Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.Semantic proximity Read ↗

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.Semantic proximity Read ↗

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemiaSemantic proximity Read ↗

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progressionSemantic proximity Read ↗

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasmsSemantic proximity Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.